Ricode

Ricode is a biotechnology company headquartered in Suzhou, China, focused on the discovery and development of RNA-targeted small molecule (rSM) therapeutics. Established in 2021, the company leverages a proprietary platform to identify small molecules capable of binding to specific RNA secondary and tertiary structures, thereby modulating gene expression at the post-transcriptional level. This approach allows Ricode to address "undruggable" targets that are inaccessible to traditional protein-binding small molecules or biologics. The company's current pipeline includes several pre-clinical programs targeting high-value indications in oncology, rare genetic disorders, and infectious diseases. Ricode is supported by leading venture capital investors, including Legend Capital and Qiming Venture Partners, and is actively expanding its R&D capabilities to advance its lead candidates toward clinical trials.